CDKN2A and urinary bladder cancer: PD- 0332991 (Palbociclib) a selective CDK 4/6 inhibitor can be used as a therapeutic target in advanced bladder cancer for p16-negative cases by controlling cell cycle progression along with or in patients resistant to traditional therapies (18).